Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBT Margin (2018 - 2026)

Sunshine Biopharma filings provide 9 years of EBT Margin readings, the most recent being 63.79% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 1998.0% to 63.79% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.44%, a 23.0% increase, with the full-year FY2025 number at 3.44%, up 23.0% from a year prior.
  • EBT Margin hit 63.79% in Q4 2025 for Sunshine Biopharma, up from 10.84% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 783.75% in Q4 2021 to a low of 15440.43% in Q1 2021.
  • Median EBT Margin over the past 5 years was 15.69% (2024), compared with a mean of 1561.11%.
  • Biggest five-year swings in EBT Margin: crashed -1459140bps in 2021 and later surged 1443245bps in 2022.
  • Sunshine Biopharma's EBT Margin stood at 783.75% in 2021, then plummeted by -175bps to 590.86% in 2022, then skyrocketed by 98bps to 13.41% in 2023, then skyrocketed by 427bps to 43.81% in 2024, then skyrocketed by 46bps to 63.79% in 2025.
  • The last three reported values for EBT Margin were 63.79% (Q4 2025), 10.84% (Q3 2025), and 21.04% (Q2 2025) per Business Quant data.